Immunara is designing nanobody-based carriers that bind to CD169 and deliver a variety of antigen formats, such as recombinant proteins, peptides, viral vectors or RNA.

At IMPACT, they create a therapy that combines patient-derived chondrons with off-the-shelf allogeneic mesenchymal stromal cells (MSCs), enabling regenerative treatment in a single surgery. This reduces both patient burden and hospital costs compared to current cell therapies.

Injectable bone filler with drug release function for treatment of bone infections (INBORN)

Incircular Biotechnologies uses its unique patented INCYPRO technology to stabilize G protein-coupled receptors (GPCRs) for reliable applications in drug discovery. This will enable the development of drug candidates for currently non-targeted GPCRs.

Liquid biopsy platform for purification and collection of intact CTCs directly from blood

An infusion set that guarantees stability and immediacy of drug administration for preterm babies

Our in-silico platform can simulate stent-retriever-based thrombectomy in various patient-specific scenarios of varying vascular anatomy and clot characteristics. This allows the medical device industries to evaluate the performance of their novel devices before pre-clinical testing.

Invision-ex has developed a bioengineered, lab-grown, human cornea tissue, offering a sustainable, accessible, long-term, and vision corrective solution.

The Overkleeft group at Leiden University discovered superior proteasome inhibitors, and it is the aim of iProtics to develop these leads to become the first-in-line treatment for Multiple Myeloma patients.

To develop early-stage antibiotic lead compounds discovered by researchers at Utrecht University. Specifically, we aim to target clinically-relevant pathogenic bacteria that have become resistant to first-line antibiotics.